Search | Clinical Trials Finder

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: Up to 17 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more

Conditions: Contraception
Interventions: Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Ovarian Suppression
Interventions: Low dose formulation, High dose formulation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ortho-Cyclen, AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Endometrial Cancer
Interventions: medroxyprogesterone, ethinyl estradiol, norgestrel, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Participants
Interventions: EE/LNG, Baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Bone Mineral Density
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 1,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more

Conditions: Temporomandibular Joint Disorders
Interventions: Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Contraception, HIV
Interventions: Levonorgestrel and Ethinyl Estradiol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bariatric Surgery Candidate, Contraception
Interventions: ethinyl estradiol-levonorgestrel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Menorrhagia
Interventions: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation; Drug · Device
Lead sponsor: Abimbola Famuyide; Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Participants
Interventions: Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Dyslipidaemia
Interventions: AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
Interventions: Levonorgestrel/ethinyl estradiol, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Dysmenorrhea
Interventions: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova), Placebo Match to SH T00658ID, Placebo Match to SH D593B; Drug
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Tucson, Arizona • San Diego, California • Hialeah, Florida + 7 more

Conditions: Healthy Volunteers
Interventions: CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG); Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

US Cycle Control and Blood Pressure Study

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Obesity, Oral Contraception, and Ovarian Suppression

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

Managing Temporomandibular Disorder (TMD) Symptoms

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

AZD6140 Oral Contraceptive Interaction Study

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Contraceptive Hormone and Reward Measurement (CHARM Study)

Effect on Primary Dysmenorrhea

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects